Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.70 |
| ▸ | CNR2 | P34972 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.70 |
| ▸ | MLNR | O43193 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.70 |
| ▸ | DRD1 | P21728 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | HRH2 | P25021 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.70 |
| ▸ | CCKAR | P32238 | 1/20 | 0.70 |
| ▸ | CCKBR | P32239 | 1/20 | 0.70 |
| ▸ | MC4R | P32245 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813468 | 1.00 | CNR1 (0.70) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Sulfuric Acid SCHEMBL4615073 | 0.99 | CNR1 (0.68) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL4614931 | 0.99 | CNR1 (0.68) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL3816397 | 0.96 | CNR1 (0.68) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Hydrochloric Acid SCHEMBL4603410 | 0.95 | CNR1 (0.68) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL4615183 | 0.94 | CNR1 (0.66) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Sulfuric Acid SCHEMBL4615539 | 0.94 | CNR1 (0.66) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL4792094 | 0.94 | CNR1 (0.60) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL3817669 | 0.93 | CNR1 (0.71) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Hydrochloric Acid SCHEMBL4617749 | 0.93 | CNR1 (0.71) | CNR1CNR2CYP2C9GPR55ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3985126-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2026-03-04 | — | — | EP | disclosed |
| EP-4355915-B1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-4680251-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Thomas Jefferson University (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-3684954-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS | GENFIT (FR) | 2025-11-26 | — | — | EP | disclosed |
| EP-3612176-B1 | COMBINATION COMPRISING THE PPAR AGONIST ELAFIBRANOR AND AN ACETYL-COA CARBOXYLASE (ACC) INHIBITOR SELECTED FROM CP-640186, GEMCABENE, GS-0976 TO TREAT INFLAMMATORY, METABOLIC, FIBROTIC OR CHOLESTATIC DISEASES | GENFIT (FR) | 2025-09-17 | — | — | EP | disclosed |
| US-20240410010-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2024-12-12 | — | — | US | disclosed |
| US-12104209-B2 | Non-invasive diagnostic of non-alcoholic steatohepatitis | GENFIT (FR) | 2024-10-01 | — | — | US | disclosed |
| WO-2024192115-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | THOMAS JEFFERSON UNIVERSITY (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| US-20240282454-A1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2024-08-22 | — | — | US | disclosed |
| CN-110536682-B | Combinations of eprinox or a derivative thereof with anti-NASH, anti-fibrosis or anti-cholestasis agents | 基恩菲特公司 | 2023-01-06 | — | — | CN | disclosed |
| WO-2022263565-A1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2022-12-22 | — | — | WO | disclosed |
| US-11519034-B2 | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis | GENFIT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-11484517-B2 | Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor | GENFIT (FR) | 2022-11-01 | — | — | US | disclosed |
| US-11478440-B2 | Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent | GENFIT (FR) | 2022-10-25 | — | — | US | disclosed |
| US-20220256821-A1 | ZEBRAFISH DELETION AND COMPOUND MUTANTS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION | 2022-08-18 | — | — | US | disclosed |
| US-20220241232-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | GENFIT (FR) | 2022-08-04 | — | — | US | disclosed |
| US-20220162702-A1 | DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2022-05-26 | — | — | US | disclosed |
| EP-3985126-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | Genfit (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3980070-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | Genfit (FR) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478440-B2 | Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent | FABP1, HDGF, HGF | CNR1 2289/4885CNR2 2490/4885CYP2C9 3582/4885 |
| US-20220241232-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | SLC10A1, CPT1A, FABP1 | CNR1 512/4885CNR2 109/4885CYP2C9 1233/4885 |
| US-20220162702-A1 | DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS | FABP1, SLC10A1, FABP2 | CNR1 1652/4885CNR2 1344/4885CYP2C9 2077/4885 |
| US-20240410010-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | FABP1, SLC10A1, FABP2 | CNR1 2438/4885CNR2 2184/4885CYP2C9 3745/4885 |
| US-11484517-B2 | Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor | ACACA, PPARA, PPARG | CNR1 466/4885CNR2 644/4885CYP2C9 951/4885 |
| US-12104209-B2 | Non-invasive diagnostic of non-alcoholic steatohepatitis | FABP1, SLC10A1, FABP2 | CNR1 2438/4885CNR2 2184/4885CYP2C9 3745/4885 |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | SLC10A1, OAT, GOT2 | CNR1 1908/4885CNR2 1761/4885CYP2C9 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.